Volumen: 20 # Number : 2
Publication Date : Mayo - Agosto Year: 2016
Frontline treatment for multiple myeloma
with RVD regimen (bortezomib, lenalidomide
and dexamethasone) for transplant-eligible and
non-transplant eligible patients for autologous
stem cell transplantation: single center experience.
Authors: X Andrade, K Oliveros, L Layedra, M Posligua, J Oliveros
Abstract: Frontline treatment for multiple myeloma (MM)
differs between transplant-eligible and non-transplant
eligible patients. The main goal is to achieve
a deeper response associated with a prolonged survival
rate. Introduction of novel therapies for MM
has significantly improved the pre-transplant complete
response rate, thus improving the prognosis of
patients receiving autologous stem cell transplant
(ASCT). In this study, we analyzed the activity and
response as well as the toxicity of the bortezomib,
lenalidomide, dexametasone (RVD) regimen in
patients with MM that are either transplant or non
transplant eligible.
Key words: Bortezomib,
Lenalidomide,
Multiple Myeloma,
Dexamethasone,
Autologous stem
cell transplantation
Pages :
|
